Ruth L Katz1, Tanweer M Zaidi1, Deep Pujara2, Namita D Shanbhag1, Duy Truong1, Shekhar Patil3, Reza J Mehran1,4, Randa A El-Zein1,5, Sanjay S Shete1,6, Joshua D Kuban1,7. 1. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Neurology, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas. 3. Department of Internal Medicine, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas. 4. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Radiology, Houston Methodist Research Institute, Houston, Texas. 6. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Approximately one third of needle biopsies that are performed to rule out malignancy of indeterminate pulmonary nodules detected radiologically during lung cancer screening are negative, thus exposing cancer-free patients to risks of pneumothorax, bleeding, and infection. A noninvasive confirmatory tool (eg, liquid biopsy) is urgently needed in the lung cancer diagnosis setting to stratify patients who should receive biopsy versus those who should be monitored. METHODS: A novel antigen-independent, 4-color fluorescence in situ hybridization (FISH)-based method was developed to detect circulating tumor cells (CTCs) with abnormalities in gene copy numbers in mononuclear cell-enriched peripheral blood samples from patients with (n = 107) and without (n = 100) lung cancer. RESULTS: Identification of CTCs using FISH probes at 10q22.3/CEP10 and 3p22.1/3q29 detected lung cancer cases with 94.2% accuracy, 89% sensitivity, and 100% specificity compared with biopsy. CONCLUSION: The high accuracy of this liquid biopsy method suggests that it may be used as a noninvasive decision tool to reduce the frequency of unnecessary needle biopsy in patients with benign pulmonary lesions.
BACKGROUND: Approximately one third of needle biopsies that are performed to rule out malignancy of indeterminate pulmonary nodules detected radiologically during lung cancer screening are negative, thus exposing cancer-free patients to risks of pneumothorax, bleeding, and infection. A noninvasive confirmatory tool (eg, liquid biopsy) is urgently needed in the lung cancer diagnosis setting to stratify patients who should receive biopsy versus those who should be monitored. METHODS: A novel antigen-independent, 4-color fluorescence in situ hybridization (FISH)-based method was developed to detect circulating tumor cells (CTCs) with abnormalities in gene copy numbers in mononuclear cell-enriched peripheral blood samples from patients with (n = 107) and without (n = 100) lung cancer. RESULTS: Identification of CTCs using FISH probes at 10q22.3/CEP10 and 3p22.1/3q29 detected lung cancer cases with 94.2% accuracy, 89% sensitivity, and 100% specificity compared with biopsy. CONCLUSION: The high accuracy of this liquid biopsy method suggests that it may be used as a noninvasive decision tool to reduce the frequency of unnecessary needle biopsy in patients with benign pulmonary lesions.
Authors: Yariswamy Manjunath; Kanve Nagaraj Suvilesh; Jonathan B Mitchem; Diego M Avella Patino; Eric T Kimchi; Kevin F Staveley-O'Carroll; Klaus Pantel; Huang Yi; Guangfu Li; Peter K Harris; Aadel A Chaudhuri; Jussuf T Kaifi Journal: JCO Precis Oncol Date: 2022-03